
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Holdings Inc. is positioned for substantial growth, with expected sales of WAKIX projected to increase from approximately $160 million in 2020 to over $700 million by 2024, driven by its safety and convenience advantages. The company is also advancing its pipeline with promising drug candidates, including pitolisant-GR, which aims to enhance treatment durability and patient adherence by eliminating the need for dose titration. Additionally, Harmony's strong balance sheet supports ongoing research and development, positioning it as a compelling growth opportunity in the neurology sector amidst the anticipated positive outcomes from multiple registrational trials.
Bears say
Harmony Biosciences Holdings Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily due to the underperformance of its pipeline, particularly ZYN002, which failed to meet the primary endpoint in the pivotal Phase 3 RECONNECT trial. The company's outlook is further hampered by the risks of increased competition in the sodium oxybate market, potential slowdowns in new patient additions for its product WAKIX, and uncertainties surrounding the success of ongoing clinical trials for several other drug candidates. Additionally, there is concern regarding the impact of an earlier-than-expected entry of generic competition for pitolisant, which could further limit growth prospects.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares